Clinical Trials on Stage III Hilar Cholangiocarcinoma AJCC v8 in United States

Total 1196 results

SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Metastatic Skin Squamous Cell Carcinoma | Metastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Refractory Malignant Neoplasm | Appendix Adenocarcinoma | Locally Advanced Malignant Neoplasm | Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Metastatic Small... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Lymph Nodes

United States
National Cancer Institute (NCI)

Active, not recruiting

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Completed

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7

United States
M.D. Anderson Cancer Center

Active, not recruiting

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen Research & Development, LLC

Active, not recruiting

Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Bladder Urothelial Carcinoma | Metastatic Kidney Carcinoma | Malignant Urinary System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Obesity | Fatigue | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Neurotoxicity Syndrome

United States, Korea, Republic of
SWOG Cancer Research Network
National Cancer Institute (NCI); Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
SWOG Cancer Research Network
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Stage II Bladder Cancer AJCC v8 | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall | Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Skin Squamous Cell Carcinoma | Unresectable Solid Neoplasm | Metastatic Kidney Medullary Carcinoma | Metastatic Penile Carcinoma | Small Cell Carcinoma | Metastatic Adrenal Gland Pheochromocytoma | Stage IV Penile Cancer... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Stage IV Renal Cell Cancer AJCC v8 | Metastatic Papillary Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Exelixis

Active, not recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract | Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Lung Adenocarcinoma | Minimally Invasive Lung Adenocarcinoma | Malignant Pleural Effusion | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Malignant Pericardial Effusion | Lung Adenosquamous Carcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
Northwestern University
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Active, not recruiting

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Progressive Disease | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Castration-Resistant Prostate Carcinoma Refractory to Second-Generation... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Leiomyosarcoma | Fibrosarcoma | Liposarcoma | Mesenchymal Chondrosarcoma | Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Malignant Peripheral Nerve Sheath Tumor | PEComa | Synovial Sarcoma | Epithelioid Sarcoma | Alveolar Soft Part Sarcoma | Undifferentiated High Grade Pleomorphic... and other conditions

United States, Canada, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
OHSU Knight Cancer Institute
Novartis Pharmaceuticals; Oregon Health and Science University

Completed

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Locally Advanced Leiomyosarcoma | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Unresectable... and other conditions

United States
National Cancer Institute (NCI)

Completed

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Recurrent Adult Soft Tissue Sarcoma | Myxofibrosarcoma | Recurrent Leiomyosarcoma | Recurrent Malignant Peripheral Nerve Sheath Tumor | Recurrent Undifferentiated Pleomorphic Sarcoma | Recurrent Liposarcoma

United States
OHSU Knight Cancer Institute
Novartis Pharmaceuticals; Oregon Health and Science University

Completed

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Adult Alveolar Soft Part Sarcoma | Adult Angiosarcoma | Adult Desmoplastic Small Round Cell Tumor | Adult Epithelioid Hemangioendothelioma | Adult Epithelioid Sarcoma | Adult Extraskeletal Myxoid Chondrosarcoma | Adult Extraskeletal... and other conditions

United States
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recurrent Endometrial Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Metastatic Endometrial Endometrioid Adenocarcinoma

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
Travera Inc
John B. Amos Cancer Center

Not yet recruiting

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Carcinoma, Renal Cell | Carcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Hepatocellular | Carcinoma, Pancreatic | Mesothelioma | AML | Cholangiocarcinoma | Stage IV Lung Cancer | Carcinoma, Neuroendocrine | Stage IV Breast Cancer | Carcinoma, Ductal | Malignant Ascites | Carcinoma Prostate | Stage III Breast Cancer and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Kidney Medullary Carcinoma | Advanced Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma

United States
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States

Clinical Trials on Stage III Hilar Cholangiocarcinoma AJCC v8 in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations